Pre-filled Syringes San Francisco Conference 2020

SMi Group 14 - 15 September 2020, San Francisco, USA.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

As part of SMi's leading Injectable conference series, we will assess digital health and connected devices, biologics, biosimilars and biocompatibility for drug device combination products, platform and device selection, regulatory insights and explore the West Coast's biotech innovators. This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

Plus, a workshop on human factors and risk management:

  • Integration of Human Factors Engineering processes in risk management saves time and money in product development
  • Effective identification of use-related risk helps inform constructive design decisions
  • Mitigation of use-related risk improves treatment outcomes for end users
  • Understanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization

Benefits of attending

  • EXPLORE the latest industry case studies in platform approaches and connected devices
  • GAIN insights from leading industry and regulatory experts on the pre-filled syringes environment
  • HEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space
  • ENGAGE in the key challenges and topics of the field in two interactive half-day workshops

Chairs for 2020

  • Shannon Clark, Principal, UserWise
  • Steven Badelt, Founder and Managing Partner, Suttons Creek, Inc.

Featured 2020 speakers include

  • Kristina Lauritsen, Combination Products Regulatory Advisor, FDA/CDER
  • Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI
  • Christine Lynn Lanning, Distinguished Scientist, Device Area Leader, Safety Assessment/Merck & Co., Inc
  • Khaudeja Bano, Senior Medical Director, Abbott Laboratories
  • Jace Blackburn, Smart Device Engineer, Genentech
  • Michael Koby, Senior Principle Scientist, Pfi zer
  • James Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
  • Walter Goodwin, Device Engineer, Device Development & Clinical Packaging Engineering, Gilead Sciences
  • Katie Atkinson, Manager Human Factors Engineering, Bigfoot Biomedical

Early-bird rates

  • Book by 29th May and save £300
  • Book by 30th June and save £200

For further information and to register, please visit:
http://www.prefilled-sanfrancisco.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...